Diagnosis and Management of Chronic Pelvic Pain Syndrome with Urinary Symptoms

Primary Diagnostic Considerations

The American Urological Association suggests that a patient with left scrotal pain, intermittent pelvic pain, daytime urinary frequency, urgency, and nighttime incontinence is likely to have Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) or Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) 1, 2
The presence of pain, pressure, or discomfort related to the bladder, associated with urinary frequency, nocturia, or an urgent desire to void, should prompt consideration of PBS/IC in men 1, 2
Pain is the hallmark symptom that differentiates PBS/IC from overactive bladder (OAB), with pelvic and scrotal pain being characteristic of PBS/IC/CP/CPPS 1, 2

The European Association of Urology recommends performing urinalysis and urine culture immediately to exclude urinary tract infection, as PBS/IC is defined by the absence of infection or other identifiable causes 1, 2, 4
Measuring post-void residual (PVR) is crucial to rule out overflow incontinence, particularly in patients with nighttime incontinence, with an elevated PVR (>250-300 mL) suggesting overflow incontinence 5
A voiding diary can help document frequency patterns, voided volumes, and timing of symptoms, distinguishing between small-volume voids (typical of PBS/IC/OAB) and large-volume voids (suggesting nocturnal polyuria) 3, 4

The American Urological Association suggests ruling out urinary tract infection, overflow incontinence, nocturnal polyuria, and bladder outlet obstruction before diagnosing PBS/IC or CP/CPPS 1, 2, 4, 5
If these conditions are excluded, the diagnosis is likely PBS/IC, CP/CPPS, or both conditions coexisting, with some men meeting criteria for both conditions 1, 2

The European Association of Urology recommends beginning treatment after a relatively short symptomatic period (6 weeks) to minimize delays, with first-line therapies including behavioral modifications and pharmacological options 1, 2
Behavioral modifications include identifying and avoiding dietary triggers, bladder training techniques, and pelvic floor physical therapy, while pharmacological options include analgesics, alpha-receptor blockers, and antimuscarinic therapy (if PVR is normal) 1, 2, 5
It is critical to measure PVR before initiating antimuscarinic therapy to avoid worsening urinary retention, with a PVR >250-300 mL indicating overflow incontinence 5

If a patient meets criteria for both PBS/IC and CP/CPPS, the treatment approach should include established PBS/IC therapies as well as therapies more specific to CP/CPPS, with empiric PBS/IC strategies potentially leading to clinical symptomatic improvement in CP/CPPS patients 1

Using research definitions requiring 6+ months of symptoms can delay treatment initiation, while failing to distinguish pain-predominant conditions (PBS/IC) from urgency-predominant conditions (OAB) can lead to misdiagnosis 1, 2
Not measuring PVR before prescribing antimuscarinics and treating with antibiotics when no infection is present are common pitfalls, as is assuming all urgency/frequency is OAB without assessing for pain 1, 2, 5